{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:32:33Z","timestamp":1793313153832,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.xphs.2026.104553","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:04:28Z","timestamp":1792623868000},"page":"104553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel non-specific binding method enables measurement of the fraction unbound of beyond rule-of-five compounds"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9623-0194","authenticated-orcid":false,"given":"Zichen","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3768-8550","authenticated-orcid":false,"given":"Aaron","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.xphs.2026.104553_bib0001","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1210\/edrv-10-3-232","article-title":"The free hormone hypothesis: a physiologically based mathematical model*","volume":"10","author":"Mendel","year":"1989","journal-title":"Endocr Rev"},{"issue":"12","key":"10.1016\/j.xphs.2026.104553_bib0002","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.xphs.2026.104553_bib0003","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1080\/17460441.2021.1961741","article-title":"An update on the importance of plasma protein binding in drug discovery and development","volume":"16","author":"Di","year":"2021","journal-title":"Expert Opin Drug Discov"},{"issue":"9","key":"10.1016\/j.xphs.2026.104553_bib0004","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S0006-2952(02)01074-2","article-title":"Predicting plasma protein binding of drugs: a new approach","volume":"64","author":"Kratochwil","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.xphs.2026.104553_bib0005","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pharmthera.2017.02.027","article-title":"Targeted protein degradation by PROTACs","volume":"174","author":"Neklesa","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.xphs.2026.104553_bib0006","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-019-0362-y","article-title":"Development of targeted protein degradation therapeutics","volume":"15","author":"Chamberlain","year":"2019","journal-title":"Nat Chem Biol"},{"issue":"3","key":"10.1016\/j.xphs.2026.104553_bib0007","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.xphs.2026.104553_bib0008","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.drudis.2020.07.013","article-title":"Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective","volume":"25","author":"Pike","year":"2020","journal-title":"Drug Discov Today"},{"issue":"5","key":"10.1016\/j.xphs.2026.104553_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100066","article-title":"Applications of contemporary tools to measure plasma protein binding of targeted protein degraders","volume":"53","author":"Niosi","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.xphs.2026.104553_bib0010","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1002\/jps.21317","article-title":"Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding","volume":"97","author":"Waters","year":"2008","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2026.104553_bib0011","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/jps.23013","article-title":"Impact of recovery on fraction unbound using equilibrium dialysis","volume":"101","author":"Di","year":"2012","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2026.104553_bib0012","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1002\/jps.24506","article-title":"Plasma protein binding of challenging compounds","volume":"104","author":"Riccardi","year":"2015","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2026.104553_bib0013","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1208\/s12248-022-00774-2","article-title":"Addressing the accuracy of plasma protein binding measurement for highly bound compounds using the dilution method","volume":"25","author":"Ryu","year":"2022","journal-title":"AAPS J"},{"issue":"8","key":"10.1016\/j.xphs.2026.104553_bib0014","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/jps.23648","article-title":"In vitro protein binding of liraglutide in Human plasma determined by reiterated stepwise equilibrium dialysis","volume":"102","author":"Plum","year":"2013","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2026.104553_bib0015","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.xphs.2020.11.018","article-title":"A novel method for preventing non-specific binding in equilibrium dialysis assays using Solutol\u00ae as an additive","volume":"110","author":"Srivastava","year":"2021","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2026.104553_bib0016","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1124\/dmd.117.078915","article-title":"Mathematical and experimental validation of flux dialysis method: an improved approach to measure unbound fraction for compounds with high protein binding and other challenging properties","volume":"46","author":"Kalvass","year":"2018","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"10.1016\/j.xphs.2026.104553_bib0017","unstructured":"ICH M12 on drug interaction studies - scientific guideline | European Medicines Agency (EMA). Accessed July 5, 2025. https:\/\/www.ema.europa.eu\/en\/ich-m12-drug-interaction-studies-scientific-guideline"},{"key":"10.1016\/j.xphs.2026.104553_bib0018","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.addr.2015.03.011","article-title":"In vitro, in silico and integrated strategies for the estimation of plasma protein binding. A review","volume":"86","author":"Lambrinidis","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"10.1016\/j.xphs.2026.104553_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2024.101175","article-title":"Characterization of preclinical radio ADME properties of ARV-471 for predicting human PK using PBPK modeling","volume":"15","author":"He","year":"2025","journal-title":"J Pharm Anal"},{"key":"10.1016\/j.xphs.2026.104553_bib0020","series-title":"All About Albumin: Biochemistry, Genetics, and Medical Applications","author":"Peters","year":"1996"},{"issue":"2","key":"10.1016\/j.xphs.2026.104553_bib0021","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1081\/DMR-100104402","article-title":"Human alpha-1-glycoprotein and its interactions with drugs","volume":"33","author":"Israili","year":"2001","journal-title":"Drug Metab Rev"},{"issue":"8","key":"10.1016\/j.xphs.2026.104553_bib0022","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/dmd.119.087163","article-title":"Plasma protein binding as an optimizable parameter for acidic drugs","volume":"47","author":"Gardiner","year":"2019","journal-title":"Drug Metab Dispos"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235492600403X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235492600403X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:54:43Z","timestamp":1793310883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235492600403X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S002235492600403X"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104553","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel non-specific binding method enables measurement of the fraction unbound of beyond rule-of-five compounds","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104553","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104553"}}